Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy
Gespeichert in:
| Veröffentlicht in: | Folia Pharmacologica Japonica 2013, Vol.142(4), pp.156-161 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161 |
|---|---|
| container_issue | 4 |
| container_start_page | 156 |
| container_title | Folia Pharmacologica Japonica |
| container_volume | 142 |
| creator | Shiose, Yoshinobu |
| description | |
| doi_str_mv | 10.1254/fpj.142.156 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443412551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1443412551</sourcerecordid><originalsourceid>FETCH-LOGICAL-j2196-ded858607d1fefdc5e6a720506e89c6cbcdcc80154867be49a8b6fa1132f71943</originalsourceid><addsrcrecordid>eNo9kMtLxDAQh4MouuievEuOXrpm2jzak8jiCxdWZMVjSZOp26Uvk1Twvzc-LzMD8_Fj5iPkFNgCUsEv6nG3AJ4uQMg9MoOMqyTPCrVPZoyBSIQs4IjMvW8qxoRKlczgkBylHJgSkM_Iy3JyDvtALb5jO4zd1-yDDpOnurd0dIMf0QQ61NROuqWP99nDRbdZP9Gm3zZVEwbnaT04anRv0NGwRafHjxNyUOvW4_y3H5Pnm-vN8i5ZrW_vl1erZJdCIROLNhe5ZMpCjbU1AqVWKRNMYl4YaSpjjcnjJzyXqkJe6LyStQbI0lpBwbNjcv6TGw99m9CHsmu8wbbVPQ6TL4HzjEdTAiJ69otOVYe2HF3TafdR_smIwOUPsIsCXvEf0C40psUyuo55acm_azT-vzFb7Urss08_Vngr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443412551</pqid></control><display><type>article</type><title>Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Shiose, Yoshinobu</creator><creatorcontrib>Shiose, Yoshinobu</creatorcontrib><identifier>ISSN: 0015-5691</identifier><identifier>EISSN: 1347-8397</identifier><identifier>DOI: 10.1254/fpj.142.156</identifier><identifier>PMID: 24107518</identifier><language>jpn</language><publisher>Japan: The Japanese Pharmacological Society</publisher><subject><![CDATA[Biomarkers, Tumor ; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage ; Class I Phosphatidylinositol 3-Kinases ; Clinical Trials as Topic ; Drug Discovery - trends ; Drug Therapy, Combination ; Humans ; Imidazoles - administration & dosage ; Molecular Targeted Therapy ; Mutation ; Neoplasms - diagnosis ; Neoplasms - drug therapy ; Neoplasms - etiology ; Neoplasms - genetics ; Phosphatidylinositol 3-Kinases - antagonists & inhibitors ; Phosphatidylinositol 3-Kinases - genetics ; Phosphatidylinositol 3-Kinases - physiology ; PTEN Phosphohydrolase - genetics ; Pyrimidines - administration & dosage ; Quinolines - administration & dosage ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; TOR Serine-Threonine Kinases - physiology]]></subject><ispartof>Folia Pharmacologica Japonica, 2013, Vol.142(4), pp.156-161</ispartof><rights>2013 by The Japanese Pharmacological Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24107518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shiose, Yoshinobu</creatorcontrib><title>Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy</title><title>Folia Pharmacologica Japonica</title><addtitle>Nihon Yakurigaku Zasshi</addtitle><subject>Biomarkers, Tumor</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - administration & dosage</subject><subject>Class I Phosphatidylinositol 3-Kinases</subject><subject>Clinical Trials as Topic</subject><subject>Drug Discovery - trends</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Imidazoles - administration & dosage</subject><subject>Molecular Targeted Therapy</subject><subject>Mutation</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - etiology</subject><subject>Neoplasms - genetics</subject><subject>Phosphatidylinositol 3-Kinases - antagonists & inhibitors</subject><subject>Phosphatidylinositol 3-Kinases - genetics</subject><subject>Phosphatidylinositol 3-Kinases - physiology</subject><subject>PTEN Phosphohydrolase - genetics</subject><subject>Pyrimidines - administration & dosage</subject><subject>Quinolines - administration & dosage</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>TOR Serine-Threonine Kinases - physiology</subject><issn>0015-5691</issn><issn>1347-8397</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtLxDAQh4MouuievEuOXrpm2jzak8jiCxdWZMVjSZOp26Uvk1Twvzc-LzMD8_Fj5iPkFNgCUsEv6nG3AJ4uQMg9MoOMqyTPCrVPZoyBSIQs4IjMvW8qxoRKlczgkBylHJgSkM_Iy3JyDvtALb5jO4zd1-yDDpOnurd0dIMf0QQ61NROuqWP99nDRbdZP9Gm3zZVEwbnaT04anRv0NGwRafHjxNyUOvW4_y3H5Pnm-vN8i5ZrW_vl1erZJdCIROLNhe5ZMpCjbU1AqVWKRNMYl4YaSpjjcnjJzyXqkJe6LyStQbI0lpBwbNjcv6TGw99m9CHsmu8wbbVPQ6TL4HzjEdTAiJ69otOVYe2HF3TafdR_smIwOUPsIsCXvEf0C40psUyuo55acm_azT-vzFb7Urss08_Vngr</recordid><startdate>201310</startdate><enddate>201310</enddate><creator>Shiose, Yoshinobu</creator><general>The Japanese Pharmacological Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201310</creationdate><title>Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy</title><author>Shiose, Yoshinobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j2196-ded858607d1fefdc5e6a720506e89c6cbcdcc80154867be49a8b6fa1132f71943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2013</creationdate><topic>Biomarkers, Tumor</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - administration & dosage</topic><topic>Class I Phosphatidylinositol 3-Kinases</topic><topic>Clinical Trials as Topic</topic><topic>Drug Discovery - trends</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Imidazoles - administration & dosage</topic><topic>Molecular Targeted Therapy</topic><topic>Mutation</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - etiology</topic><topic>Neoplasms - genetics</topic><topic>Phosphatidylinositol 3-Kinases - antagonists & inhibitors</topic><topic>Phosphatidylinositol 3-Kinases - genetics</topic><topic>Phosphatidylinositol 3-Kinases - physiology</topic><topic>PTEN Phosphohydrolase - genetics</topic><topic>Pyrimidines - administration & dosage</topic><topic>Quinolines - administration & dosage</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>TOR Serine-Threonine Kinases - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shiose, Yoshinobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Folia Pharmacologica Japonica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shiose, Yoshinobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy</atitle><jtitle>Folia Pharmacologica Japonica</jtitle><addtitle>Nihon Yakurigaku Zasshi</addtitle><date>2013-10</date><risdate>2013</risdate><volume>142</volume><issue>4</issue><spage>156</spage><epage>161</epage><pages>156-161</pages><issn>0015-5691</issn><eissn>1347-8397</eissn><cop>Japan</cop><pub>The Japanese Pharmacological Society</pub><pmid>24107518</pmid><doi>10.1254/fpj.142.156</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0015-5691 |
| ispartof | Folia Pharmacologica Japonica, 2013, Vol.142(4), pp.156-161 |
| issn | 0015-5691 1347-8397 |
| language | jpn |
| recordid | cdi_proquest_miscellaneous_1443412551 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Biomarkers, Tumor Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Class I Phosphatidylinositol 3-Kinases Clinical Trials as Topic Drug Discovery - trends Drug Therapy, Combination Humans Imidazoles - administration & dosage Molecular Targeted Therapy Mutation Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - etiology Neoplasms - genetics Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - genetics Phosphatidylinositol 3-Kinases - physiology PTEN Phosphohydrolase - genetics Pyrimidines - administration & dosage Quinolines - administration & dosage TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - physiology |
| title | Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A02%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20development%20status%20and%20prospect%20of%20dual%20PI3K/mTOR%20inhibitors%20for%20cancer%20therapy&rft.jtitle=Folia%20Pharmacologica%20Japonica&rft.au=Shiose,%20Yoshinobu&rft.date=2013-10&rft.volume=142&rft.issue=4&rft.spage=156&rft.epage=161&rft.pages=156-161&rft.issn=0015-5691&rft.eissn=1347-8397&rft_id=info:doi/10.1254/fpj.142.156&rft_dat=%3Cproquest_pubme%3E1443412551%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1443412551&rft_id=info:pmid/24107518&rfr_iscdi=true |